BICR 56Homo sapiens (Human)Cancer cell line

Also known as: Beatson Institute for Cancer Research 56, BICR56, BICR-56

🤖 AI SummaryBased on 7 publications

Quick Overview

Human squamous cell carcinoma cell line with p53 mutations and immortal characteristics.

Detailed Summary

BICR 56 is a human squamous cell carcinoma cell line derived from head and neck squamous cell carcinoma (SCC-HN). It exhibits immortal characteristics, with a high proliferative capacity in vitro. The cell line shows p53 mutations, which are associated with the loss of wild-type p53 function and potential implications in tumor progression. BICR 56 has been studied for its genetic alterations, including loss of heterozygosity (LOH) at specific chromosomal loci, such as 3p21.2-p21.3 and 4q32-q34, which are linked to tumor suppressor gene inactivation. These genetic changes may contribute to the immortalization and malignant potential of the cell line. Research on BICR 56 has focused on understanding the molecular mechanisms of SCC-HN development, including the role of p53 and other tumor suppressor genes in cellular immortality and cancer progression.

Research Applications

Cancer ResearchGenetic Mutations AnalysisTumor Suppressor Gene StudiesCell Immortality Mechanisms

Key Characteristics

Immortalp53 MutationsLoss of Heterozygosity (LOH) at 3p21.2-p21.3 and 4q32-q34High Proliferative Capacity

Generated on 6/18/2025

Basic Information

Database ID	CVCL_2313
Species	Homo sapiens (Human)
Tissue Source	Oral cavity, tongue[UBERON:UBERON_0001723]

Donor Information

Age Category	Unknown
Sex	Female
Race	caucasian

Disease Information

Disease	Squamous cell carcinoma of the oral tongue
Lineage	Head and Neck
Subtype	Oral Cavity Squamous Cell Carcinoma
OncoTree Code	OCSC

DepMap Information

Source Type	ECACC
Source ID	ACH-000771_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	c.376-1G>A (p.Tyr126_Lys132del, c.376_396del21)	Unspecified	Splice acceptor mutation	from parent cell line U-1285

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

CSF1PO

D13S317

D16S539

D5S818

11,12

D7S820

8,12

TH01

9,9.3

TPOX

8,9

vWA

15,16

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Next-generation characterization of the Cancer Cell Line Encyclopedia.

Sellers W.R.

Nature 569:503-508(2019).

DOI PubMed PMC

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.

Loewer M., Sahin U., Castle J.C.

Genome Med. 7:118.1-118.7(2015).

DOI PubMed PMC

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.

Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.

Nature 483:603-607(2012).

DOI PubMed PMC

Increased dosage and amplification of the focal adhesion kinase gene in human cancer cells.

Keith W.N., Frame M.C.

Oncogene 18:5646-5653(1999).

DOI PubMed

Inappropriate retinoic acid receptor-beta expression in oral dysplasias: correlation with acquisition of the immortal phenotype.

Harrison P.R.

Cancer Res. 57:3886-3889(1997).

PubMed

Evidence for the inactivation of multiple replicative lifespan genes in immortal human squamous cell carcinoma keratinocytes.

Parkinson E.K.

Oncogene 14:1955-1964(1997).

DOI PubMed

Gene mutations and increased levels of p53 protein in human squamous cell carcinomas and their cell lines.

Chapman C., Mitchell R., Robertson G., Soutar D., Parkinson E.K.

Br. J. Cancer 67:1274-1284(1993).

DOI PubMed PMC

Cellular immortality: a late event in the progression of human squamous cell carcinoma of the head and neck associated with p53 alteration and a high frequency of allele loss.

Edington K.G., Loughran O.P., Berry I.J., Parkinson E.K.

Mol. Carcinog. 13:254-265(1995).

DOI PubMed